Phase 1, single-center, randomized, comparative trial of single doses of IV rezafungin, IV placebo, and oral moxifloxacin (positive control) in healthy adult subjects
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Rezafungin (Primary) ; Moxifloxacin
- Indications Aspergillosis; Candidiasis
- Focus Adverse reactions
- 12 Oct 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018